Piper Jaffray Maintains Overweight on Advisory Board

Piper Jaffray is out with its report today on Advisory Board ABCO, maintaining Overweight. In a note to clients, Piper Jaffray writes, "Following a two day marketing trip with the company's CEO and CFO, we are incrementally more confident in the company's opportunity, as we enter into a period of uncertainty in the healthcare industry. Increasing complexity and changes in healthcare are providing a significant tailwind for the company to serve hospitals, as evidenced by the high renewal rate and growth in contract value in the recent quarter. We expect that growth to continue and believe that the company can expand margins while growing the top line (mid-teens) and investing in new tools offerings. At mid-teens top-line growth and 20% EBITDA margins, we see significant upside to CY12 Street estimates. Maintain Overweight, $60 Target." Shares of ABCO closed Wednesday at $50.65, up 0.82% from Tuesday's close.